INTRON A FOR MALIGNANT MELANOMA PROVIDES INCREASED OVERALL SURVIVAL; CMTE. RECOMMENDS WIDER INDICATION OF USE IN DISEASE-FREE, HIGH-RISK PATIENTS
Executive Summary
Schering-Plough data on Intron A show interferon-alpha 2b extends overall survival in patients with malignant melanoma by one year and provides a nine-month median increase in relapse-free survival.